BioCentury
ARTICLE | Clinical News

GGTI-2418: Phase I start

March 9, 2009 7:00 AM UTC

This quarter, Tigris will begin a dose-escalation, U.S. Phase I trial to evaluate GGTI-2418 in 25-40 patients. Tigris has exclusive, worldwide rights to the compound from the University of South Flori...